Literature DB >> 7587851

1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM.

M Kishimoto1, Y Yamasaki, M Kubota, K Arai, T Morishima, R Kawamori, T Kamada.   

Abstract

OBJECTIVE: To evaluate the usefulness of plasma 1,5-anhydro-D-glucitol (1,5-AG) as a possible marker for daily glycemic excursion, we measured plasma 1,5-AG, HbA1c, fasting plasma glucose (FPG) level, and daily excursion of glycemia, from which the M-value (after Schlichtkrull) was calculated as an index of daily glycemic excursion. RESEARCH DESIGN AND METHODS: The subjects were 76 patients with well-controlled non-insulin-dependent diabetes mellitus (NIDDM) treated with diet therapy only (diet, n = 17), oral hypoglycemic agents (OHA, n = 28), conventional insulin therapy (CIT, n = 16), or multiple insulin injection therapy (MIT, n = 15).
RESULTS: HbA1c values were similar among all the groups (diet, 6.9 +/- 0.6; OHA, 7.2 +/- 0.5; CIT, 7.1 +/- 0.6; MIT, 7.2 +/- 0.5%). The MIT group showed a significantly higher 1,5-AG concentration (11.5 +/- 5.3 micrograms/ml), a significantly lower M-value (9.2 +/- 5.2), and little risk of hypoglycemia ( < 4 mmol/l) and hyperglycemia ( > 10 mmol/l) (1.3 +/- 1.1 times/24 h) compared with the CIT group (6.9 +/- 3.3 micrograms/ml, 15.7 +/- 8.9, 2.2 +/- 1.6 times/24 h, respectively). Insulin doses (22.4 +/- 4.5 vs. 22.0 +/- 8.9 U/day), FPG (6.6 +/- 2.2 vs. 7.4 +/- 2.4 mmol/l), and HbA1c concentrations were not significantly different between the CIT and MIT groups. M-values significantly correlated with 1,5-AG concentrations (r = 0.414, P < 0.05), but not with HbA1c concentrations.
CONCLUSIONS: The findings suggest that the plasma 1,5-AG concentration can be a useful index of the daily excursion of blood glucose, especially in patients with well-controlled NIDDM.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7587851     DOI: 10.2337/diacare.18.8.1156

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  20 in total

1.  The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoring.

Authors:  Roy Beck; Michael Steffes; Dongyuan Xing; Katrina Ruedy; Nelly Mauras; Darrell M Wilson; Craig Kollman
Journal:  Pediatr Diabetes       Date:  2011-04-17       Impact factor: 4.866

2.  1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics.

Authors:  Gesiane Tavares; Gabriela Venturini; Kallyandra Padilha; Roberto Zatz; Alexandre C Pereira; Ravi I Thadhani; Eugene P Rhee; Silvia M O Titan
Journal:  Metabolomics       Date:  2018-02-27       Impact factor: 4.290

Review 3.  Utility of different glycemic control metrics for optimizing management of diabetes.

Authors:  Klaus-Dieter Kohnert; Peter Heinke; Lutz Vogt; Eckhard Salzsieder
Journal:  World J Diabetes       Date:  2015-02-15

4.  The establishment of biological reference intervals of nontraditional glycemic markers in a Chinese population.

Authors:  Qiang Zhou; De-Bao Shi; Li-Ying Lv
Journal:  J Clin Lab Anal       Date:  2016-11-17       Impact factor: 2.352

Review 5.  Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol.

Authors:  Ji-Eun Lee
Journal:  Ann Pediatr Endocrinol Metab       Date:  2015-06-30

Review 6.  1,5-Anhydroglucitol in diabetes mellitus.

Authors:  Won Jun Kim; Cheol-Young Park
Journal:  Endocrine       Date:  2012-07-31       Impact factor: 3.633

Review 7.  Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes.

Authors:  Toshikazu Yamanouchi
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

8.  Association of 1,5-anhydroglucitol with diabetes and microvascular conditions.

Authors:  Elizabeth Selvin; Andreea M Rawlings; Morgan Grams; Ronald Klein; Michael Steffes; Josef Coresh
Journal:  Clin Chem       Date:  2014-09-08       Impact factor: 8.327

9.  Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk.

Authors:  Takayuki Fujiwara; Masashi Yoshida; Hodaka Yamada; Takunori Tsukui; Tomohiro Nakamura; Kenichi Sakakura; Hiroshi Wada; Kenshiro Arao; Takuji Katayama; Hiroshi Funayama; Yoshitaka Sugawara; Takeshi Mitsuhashi; Masafumi Kakei; Shin-Ichi Momomura; Junya Ako
Journal:  Heart Vessels       Date:  2014-04-02       Impact factor: 2.037

10.  A study on the association of serum 1,5-anhydroglucitol levels and the hyperglycaemic excursions as measured by continuous glucose monitoring system among people with type 2 diabetes in China.

Authors:  Y Wang; Y L Zhang; Y P Wang; C H Lei; Z L Sun
Journal:  Diabetes Metab Res Rev       Date:  2012-05       Impact factor: 4.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.